147 related articles for article (PubMed ID: 36310058)
41. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
[TBL] [Abstract][Full Text] [Related]
42. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.
Kaito S; Iwama A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374737
[TBL] [Abstract][Full Text] [Related]
43. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N
Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328
[TBL] [Abstract][Full Text] [Related]
44. Ezh1 arises from Ezh2 gene duplication but its function is not required for zebrafish development.
Völkel P; Bary A; Raby L; Chapart A; Dupret B; Le Bourhis X; Angrand PO
Sci Rep; 2019 Mar; 9(1):4319. PubMed ID: 30867490
[TBL] [Abstract][Full Text] [Related]
45. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
Dou L; Yan F; Pang J; Zheng D; Li D; Gao L; Wang L; Xu Y; Shi J; Wang Q; Zhou L; Shen N; Singh P; Wang L; Li Y; Gao Y; Liu T; Chen C; Al-Kali A; Litzow MR; Chi YI; Bode AM; Liu C; Huang H; Liu D; Marcucci G; Liu S; Yu L
Nat Commun; 2019 Nov; 10(1):5051. PubMed ID: 31699991
[TBL] [Abstract][Full Text] [Related]
46. Maternal Ezh1/2 deficiency in oocyte delays H3K27me2/3 restoration and impairs epiblast development responsible for embryonic sub-lethality in mouse.
Zhao Y; Bai D; Wu Y; Zhang D; Liu M; Tian Y; Lu J; Wang H; Gao S; Lu Z
Development; 2022 Aug; 149(15):. PubMed ID: 35796552
[TBL] [Abstract][Full Text] [Related]
47. Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.
Lau-Corona D; Bae WK; Hennighausen L; Waxman DJ
PLoS Genet; 2020 May; 16(5):e1008796. PubMed ID: 32428001
[TBL] [Abstract][Full Text] [Related]
48. EZH1/2 as targets for cancer therapy.
An R; Li YQ; Lin YL; Xu F; Li MM; Liu Z
Cancer Gene Ther; 2023 Feb; 30(2):221-235. PubMed ID: 36369341
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
50. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.
Lee CH; Holder M; Grau D; Saldaña-Meyer R; Yu JR; Ganai RA; Zhang J; Wang M; LeRoy G; Dobenecker MW; Reinberg D; Armache KJ
Mol Cell; 2018 May; 70(3):435-448.e5. PubMed ID: 29681498
[TBL] [Abstract][Full Text] [Related]
51. Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2.
Song Z; Wu W; Chen M; Cheng W; Yu J; Fang J; Xu L; Yasunaga JI; Matsuoka M; Zhao T
J Virol; 2018 Dec; 92(24):. PubMed ID: 30258009
[TBL] [Abstract][Full Text] [Related]
52. Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57
Li W; Bi C; Han Y; Tian T; Wang X; Bao H; Xu X; Zhang X; Liu L; Zhang W; Gao H; Wang H; Zhang H; Meng B; Wang X; Fu K
Cancer Biol Med; 2019 Aug; 16(3):530-541. PubMed ID: 31565482
[TBL] [Abstract][Full Text] [Related]
53. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
[TBL] [Abstract][Full Text] [Related]
54. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
[TBL] [Abstract][Full Text] [Related]
55. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
56. Divergent Requirements for EZH1 in Heart Development Versus Regeneration.
Ai S; Yu X; Li Y; Peng Y; Li C; Yue Y; Tao G; Li C; Pu WT; He A
Circ Res; 2017 Jul; 121(2):106-112. PubMed ID: 28512107
[TBL] [Abstract][Full Text] [Related]
57. Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition.
Yu L; Wang YF; Xiao J; Shen QQ; Chi SS; Gao YL; Lin DZ; Ding J; Fang YF; Chen Y
Acta Pharmacol Sin; 2023 Oct; 44(10):2113-2124. PubMed ID: 37225847
[TBL] [Abstract][Full Text] [Related]
58. [Novel epigenetic therapies for multiple myeloma].
Mimura N
Rinsho Ketsueki; 2021; 62(4):314-320. PubMed ID: 33967157
[TBL] [Abstract][Full Text] [Related]
59. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
[TBL] [Abstract][Full Text] [Related]
60. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
